Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Extension of Obeticholic Acid + Bezafibrate in Primary Biliary Cholangitis
2023-507771-22-01Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of obeticholic acid and bezafibrate in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Feb 2025; status: completed.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2023-507771-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507771-22-01.